Tokolitik Tedavide Güncel Yaklaşımlar

Öz

Uzun yıllardır kullanılmakta olan tokolitik ajanların, son literatür bilgileri ile etkinliği ve yan etkilerinin değerlendirilerek; ilk tercih edilmesi gereken tokolitik ajanın belirlemeyi amaçladık. Erken doğum eylemi tanısı ile izlenen hastalarda uygulanan tıbbi tedavilerden ß agonistler, Ca kanal blokerleri ve atosibana göre daha fazla yan etkiye neden olmakta, atosiban ise yan etkisi daha az ve ruhsatlı olmasına rağmen daha pahalı olması dezavantajını taşımaktadır. Nifedipin için hala ruhsatlı olmaması doz çalışmalarının yapılmamış olması dezavantajları olarak görülmektedir. Sonuç olarak ilk tercih edilmesi gereken tokolitik tedavi henüz belirlenememiş olup geniş kapsamlı randomize çalışmalara ihtiyaç duyulmaktadır.

Anahtar Kelimeler

• Tokoliz, Ca kanal blokerleri, ß agonistler, MgSO4

Kaynakça

1. IOM report of preterm birth [http://newton.nap.edu/catalog/11622].
2. Editorial: Preterm birth: crisis and opportunity. Lancet. 2006, 368:339.
3. Magowan BA, Bain M, Juszczak E, McInneny K. Neonatal mortality amongst Scottish preterm singleton births (1985-1994). Br J Obstet Gynaecol. 1998; 105: 1005e10.
4. Blom SL, Yost NP, McIntire DD, Leveno KJ. Recurence of preterm birth in singleton and twin pregnancies. Obstet Gynecol. 2001; 98(3): 379-85.
5. Tara PN, Thornton S. Current medical therapy in the prevention and treatment of preterm labour. Seminars in Fetal Neonatal Med. 2004; 9: 481-89.
6. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003; 188: 419e24.
7. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alphahydroxyprogesterone caproate. N Engl J Med. 2003; 348(24): 2379-85.
8. Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol. 2009; 200(3): 219-24.

9. Whitelaw A, Thoresen M. Antenatal steroids and the developing brain. Arch Dis Child Fetal Neonatal Ed. 2000; 83:F154e7.
10. Keirse MJ. The history of tocolysis. Br J Obstet Gynaecol. 2003; 110(Suppl 20): 94-7.
11. Ulmsten U, Andersson KE, Wingerup L. Treatment of premature labor with the calcium antagonist nifedipine. Arch Gynecol. 1980; 229: 1-5.
12. Vaast P, Dubreucq-Fossaert S, Houfflin-Debarge V, Provost-Helou N, Ducloy-Bouthors AS, Puech F, Subtil D. Acute pulmonary oedema during nicardipine therapy for preterm labour, report of 5 cases. Eur J Obstet Gynaecol. 2004; 113(1): 98-9.
13. Oei SG. Calcium channel blockers for vtocolysis: A review of their role and safety following reports of serious adverse events. Eur J Obstet Gynaecol Reprod Biol. 2006; 126: 137-45.
14. van Veen AJ, Pelinck PJ, Pampus MG, Erwich JJ. Severe hypotension and fetal death due to tocolysis with nifedipine. Br J Obstet Gynaecol. 2005; 112: 509-10.
15. Impey L. Severe hypotension and tal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol. 1993; 100: 9599-61.
16. King JF, Flenady V, Papatsonis D, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour: A systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol. 2003; 43(3): 192-8.
17. Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U, Burrs D, Caughey AB, El-Sayed YY. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: A randomized controlled trial. Obstet Gynecol. 2007; 110(1): 61-7.
18. King JF, Flenady VJ, Papatsonis DNM, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2003.
19. Gabor H, James MR. Biochemistry and pharmacology of the myometrium and labor: regulation at the cellular and molecular levels. American Journal of Obstetrics and Gynecology. 1982; 142: 225–37.
20. Anotayanonth S, Subhedar NV, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews. 2004; 18(4): CD004352.
21. Besinger R, Lannucci T. Tocolytic therapy. In: Elder MG, Lamont RF, Romero R, editors. Preterm Labor. New York: Churchill Livingstone; 1997: 243-97.
22. Dodd JM, Crowther CA, Dare MR, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database of Systematic Reviews. 2006; 25(1): CD003927.
23. Macones GA, Berlin M, Berlin JA. Efficacy of oral beta-agonist maintenance therapy in preterm labor: A meta-analysis. Obstet Gynecol. 1995; 85(2): 313-7.
24. Donders GG, Van Keirsbilck J, De Roo T, Scheveren L, Hanssens M. Non-cardiogenic lung edema in awoman treated with atosiban for preterm labor. J Perinat Med 2008; 36(5):455-7.
25. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventingpreterm birth in threatened preterm labour [Cochrane review]. The Cochrane Library 2002; Issue 4. Chichester, UK: John Wiley & Sons, Ltd.
26. Mittendorf R, Pryde PG. A review of the role for magnesium sulphate in preterm labour. Br J Obstet Gynaecol. 2005; 112: 84-8.
27. Simhan HN, Caritis SN. Prevention of preterm delivery. N Eng J Med. 2007; 357: 477-87.
28. Lees CC, Lojacono A, Thompson C, Danti L, Black RS, Tanzi P, White IR, Campbell S. Glyceryl trinitrate and ritodrine in tocolysis: an international multicenter randomized study. Obstet Gynecol. 1999; 94(3): 403-8.
29. Smith GN, Walker MC, McGrath MJ. Randomised, double-blind, placebo controlled pilot study assessing nitroglycerin as a tocolytic. Br J Obstet Gynaecol. 1999; 106: 736-9.
30. King J, Flenady V, Cole S, Thornton S. Cyclo-axygenase(cox) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005; 18(2): CD001992.
31. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour [Cochrane review]. The Cochrane Library 2004: 3. Chichester, UK: John Wiley & Sons, Ltd.
32. Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis. Asystematic review with meta-analysis. Obstet Gynecol. 2005; 106: 173-9.
33. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev. 2005; 20(3): CD004452.
34. Donders GG, Van Keirsbilck J, De Roo T, Scheveren L, Hanssens M. Non-cardiogenic lung edema in awoman treated with atosiban for preterm labor. J Perinat Med. 2008; 36(5): 455-7.
35. Neri I, Monari F, Valensise H, Vasapollo B, Facchinetti F, Volpe A. Computerized evaluation of fetal heart rate during tocolytic treatment: comparison between atosiban and ritodrine. Am J Perinatol. 2009; 26(4): 259-63.
36. Kashanian M, Akbaria AR, Soltanzadeh M. Atosiban and nifedipine for the treatment of preterm labor. Int J Gynaecol Obstet Int. 2005; 91: 10-14.
37. American College of Obstetricians and Gynecologists (ACOG). Management of preterm labor. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2003 May. 9 p. (ACOG practice bulletin; no. 43). Royal College of Obstetricians and Gynaecologists. Clinical Guideline No. 1(B) 2002.
38. Parant O, Maillard F, Tsatsarir V, Delattre M, Subtil D, Goffinet F on behalf of the EVAPRIMA Group. Management of threatened preterm delivery in France: a national practice survey (the EVAPRIMA study). Br J Obstet Gynaecol. 2008; 115: 1538-46.